

Dear Editor,

We are excited to have been given the opportunity to revise our manuscript, which is entitled “Role of Pre-transplant 18F-FDG PET/CT in Predicting Hepatocellular Carcinoma Recurrence After Liver Transplantation”. First, we would like to thank all reviewers for the time and effort that they invested into the review of our manuscript, and for their helpful comments and suggestions, which we carefully considered. The corrections made and newly added references are indicated with red letters in the revised manuscript. Herein, we explain how we revised the paper based on those comments and recommendations.

Reviewer #1:

1. Yes, we have meant the selection of HCC patients. This was corrected in the manuscript accordingly.
2. We have corrected the minor grammatical error.

Reviewers #2 and #3:

We would like to thank both reviewers for their appreciation of our manuscript.

Reviewer #4:

We would like to thank the reviewer for the insightful comments.

1. Definitions for clinically significant PET/CT positivity have been added to the manuscript both within the text and all new data is shown in a separate new table (Table 4).
2. Data on the efficacy of PET/CT in recurrent and extrahepatic lesions in HCC patients have also been added.

Reviewer #5:

We would like to thank the reviewer for bringing the issue of dual tracers and Primovist MRI scan, so that we had the chance to add a new dimension to the manuscript.

1. New data comparing the Primovist MRI and PET scan is added to the text
2. The role of dual-tracers (18F-FDG and C11-Acetate)-PET scan is added to the text

Sincerely,

Murat Dayangac, MD

Professor of Surgery

Medipol University Hospital

Center for Organ Transplantation